Home    Back

Baminercept    (DrugBank: Baminercept)

4 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica1
46Malignant rheumatoid arthritis2
53Sjogren syndrome1
97Ulcerative colitis4

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 3,050 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01181089
(ClinicalTrials.gov)		September 20105/8/2010Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)A Multicenter, Randomized, Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF) and Safety in Subjects With Secondary Progressive Multiple SclerosisSecondary Progressive Multiple SclerosisBiological: Placebo;Biological: BaminerceptBiogen IdecNULLWithdrawn18 Years57 YearsBoth0Phase 1;Phase 2Canada;United Kingdom

46. Malignant rheumatoid arthritis    [ 4,183 clinical trials,   2,538 drugs,   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways]
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 4,183 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00664573
(ClinicalTrials.gov)		November 200721/4/2008Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) PatientsAssessment of Safety and Efficacy of BG9924 in Subjects With RA Who Have Participated in Study 104RA202.Rheumatoid ArthritisBiological: Baminercept alfa (BG9924)Biogen IdecNULLTerminated18 Years75 YearsBoth339Phase 2Argentina;Brazil;Hungary;Mexico;Poland;Romania;Russian Federation;United Kingdom
2NCT00664716
(ClinicalTrials.gov)		July 200721/4/2008Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) PatientsAssessment Of Safety, Efficacy, PK&PD Of BG9924 in RA Patients Who Have Had An Inadequate Response To Conventional DMARD Therapy.Rheumatoid ArthritisBiological: Placebo;Biological: baminercept alfa;Biological: Baminercept alfaBiogen IdecNULLCompleted18 Years75 YearsBoth391Phase 2Argentina;Brazil;Hungary;Mexico;Poland;Romania;Russian Federation;United Kingdom

53. Sjogren syndrome    [ 234 clinical trials,   270 drugs,   (DrugBank: 85 drugs),   49 drug target genes,   174 drug target pathways]
Searched query = "Sjogren syndrome", "Sjögren syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 234 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01552681
(ClinicalTrials.gov)		July 20129/3/2012Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's SyndromeA Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Baminercept, a Lymphotoxin-beta Receptor Fusion Protein, for the Treatment of Primary Sjögren's Syndrome (ASJ02)Primary Sjögren's SyndromeBiological: Baminercept;Other: PlaceboNational Institute of Allergy and Infectious Diseases (NIAID)Autoimmunity Centers of Excellence;BiogenTerminated18 Years75 YearsAll52Phase 2United States

97. Ulcerative colitis    [ 2,269 clinical trials,   1,331 drugs,   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways]
Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 2,269 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2010-019558-42-SK
(EUCTR)		23/02/201127/10/2010A Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety, and Tolerability of Baminercept in Subjects With Moderate to Severe Ulcerative ColitisA Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety, and Tolerability of Baminercept in Subjects With Moderate to Severe Ulcerative Colitis Ulcerative Colitis
MedDRA version: 12.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis		Product Name: Baminercept
Product Code: BG9924
INN or Proposed INN: N/A
Other descriptive name: Baminercept		Biogen Idec Ltd.NULLNot RecruitingFemale: yes
Male: yes		100Phase 2Hungary;Czech Republic;Slovakia;Belgium
2EUCTR2010-019558-42-HU
(EUCTR)		20/01/201110/11/2010A Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety, and Tolerability of Baminercept in Subjects With Moderate to Severe Ulcerative ColitisA Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety, and Tolerability of Baminercept in Subjects With Moderate to Severe Ulcerative Colitis Ulcerative Colitis
MedDRA version: 12.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis		Product Name: Baminercept
Product Code: BG9924
INN or Proposed INN: N/A
Other descriptive name: Baminercept		Biogen Idec Ltd.NULLNot RecruitingFemale: yes
Male: yes		100Hungary;Czech Republic;Belgium
3EUCTR2010-019558-42-CZ
(EUCTR)		10/01/201125/10/2010A Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety, and Tolerability of Baminercept in Subjects With Moderate to Severe Ulcerative ColitisA Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety, and Tolerability of Baminercept in Subjects With Moderate to Severe Ulcerative Colitis Ulcerative Colitis
MedDRA version: 12.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis		Product Name: Baminercept
Product Code: BG9924
INN or Proposed INN: N/A
Other descriptive name: Baminercept		Biogen Idec Ltd.NULLNot RecruitingFemale: yes
Male: yes		100Hungary;Czech Republic;Belgium
4EUCTR2010-019558-42-BE
(EUCTR)		23/12/201013/10/2010A Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety, and Tolerability of Baminercept in Subjects With Moderate to Severe Ulcerative ColitisA Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety, and Tolerability of Baminercept in Subjects With Moderate to Severe Ulcerative Colitis Ulcerative Colitis
MedDRA version: 12.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis		Product Name: Baminercept
Product Code: BG9924
INN or Proposed INN: N/A
Other descriptive name: Baminercept		Biogen Idec Ltd.NULLNot RecruitingFemale: yes
Male: yes		100Hungary;Czech Republic;Belgium

Back to top